Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 157

1.

Potential Role of OCT4 in Leukemogenesis.

Picot T, Kesr S, Wu Y, Aanei CM, Flandrin-Gresta P, Tondeur S, Tavernier E, Wattel E, Guyotat D, Campos L.

Stem Cells Dev. 2017 Nov 15;26(22):1637-1647. doi: 10.1089/scd.2017.0134. Epub 2017 Oct 16.

PMID:
28911263
2.

Expression of embryonic stem cell markers in acute myeloid leukemia.

Picot T, Aanei CM, Fayard A, Flandrin-Gresta P, Tondeur S, Gouttenoire M, Tavernier-Tardy E, Wattel E, Guyotat D, Campos L.

Tumour Biol. 2017 Jul;39(7):1010428317716629. doi: 10.1177/1010428317716629.

PMID:
28718379
3.

[Effects of Geriatric COPD rehabilitation on hospital admissions and exercise tolerance: a retrospective observational study].

Blindenbach S, Vrancken JWFA, van der Zeijden H, Reesink HJ, Brijker F, Smalbrugge M, Wattel EM.

Tijdschr Gerontol Geriatr. 2017 Jun;48(3):112-120. doi: 10.1007/s12439-017-0214-8. Dutch.

PMID:
28447319
4.

Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.

Park S, Hamel JF, Toma A, Kelaidi C, Thépot S, Campelo MD, Santini V, Sekeres MA, Balleari E, Kaivers J, Sapena R, Götze K, Müller-Thomas C, Beyne-Rauzy O, Stamatoullas A, Kotsianidis I, Komrokji R, Steensma DP, Fensterl J, Roboz GJ, Bernal T, Ramos F, Calabuig M, Guerci-Bresler A, Bordessoule D, Cony-Makhoul P, Cheze S, Wattel E, Rose C, Vey N, Gioia D, Ferrero D, Gaidano G, Cametti G, Pane F, Sanna A, Germing U, Sanz GF, Dreyfus F, Fenaux P.

J Clin Oncol. 2017 May 10;35(14):1591-1597. doi: 10.1200/JCO.2016.71.3271. Epub 2017 Mar 28.

PMID:
28350519
5.

TET2 exon 2 skipping is an independent favorable prognostic factor for cytogenetically normal acute myelogenous leukemia (AML): TET2 exon 2 skipping in AML.

Mohamed AM, Balsat M, Koering C, Maucort-Boulch D, Boissel N, Payen-Gay L, Cheok M, Mortada H, Auboeuf D, Pinatel C, El-Hamri M, Tigaud I, Hayette S, Dumontet C, Cros E, Flandrin-Gresta P, Nibourel O, Preudhomme C, Thomas X, Nicolini FE, Solly F, Guyotat D, Campos L, Michallet M, Ceraulo A, Mortreux F, Wattel E.

Leuk Res. 2017 May;56:21-28. doi: 10.1016/j.leukres.2017.01.012. Epub 2017 Jan 16.

PMID:
28167452
6.

Management of psychiatric complications in unrelated donor before unrelated peripheral hematopoietic stem cell collections.

Hequet O, Mialou V, Audat F, Wattel E, Chapel V, Revesz D, Jouet JP, Fisseaux B, Saoud M, Michallet M.

J Blood Med. 2016 Dec 30;8:1-4. doi: 10.2147/JBM.S96465. eCollection 2017.

7.

Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the Groupe Francophone Des Myélodysplasies.

Ades L, Prebet T, Stamatoullas A, Recher C, Guieze R, Raffoux E, Bouabdallah K, Hunault M, Wattel E, Stalnikiewicz L, Toma A, Dombret H, Vey N, Sebert M, Gardin C, Chaffaut C, Chevret S, Fenaux P.

Haematologica. 2017 Apr;102(4):728-735. doi: 10.3324/haematol.2016.151894. Epub 2016 Dec 29.

8.

Fractionated gemtuzumab ozogamicin combined with intermediate-dose cytarabine and daunorubicin as salvage therapy in very high-risk AML patients: a bridge to reduced intensity conditioning transplant?

Paubelle E, Ducastelle-Leprêtre S, Labussière-Wallet H, Nicolini FE, Barraco F, Plesa A, Salles G, Wattel E, Thomas X.

Ann Hematol. 2017 Mar;96(3):363-371. doi: 10.1007/s00277-016-2899-0. Epub 2016 Dec 23.

PMID:
28011984
9.

Addition of suberoylanilide hydroxamic acid (Vorinostat) to azacitidine for patients with higher risk myelodysplastic syndromes and azacitidine failure: a phase II add-on study from the Groupe Francophone des Myelodysplasies.

Prebet T, Delaunay J, Wattel E, Braun T, Cony-Makhoul P, Dimicoli S, Wickenhauser S, Lejeune J, Chevret S, Chermat F, Fenaux P, Vey N; Groupe Francophone des Myélodysplasies.

Br J Haematol. 2018 Mar;180(5):735-737. doi: 10.1111/bjh.14427. Epub 2016 Dec 15. No abstract available.

PMID:
27977052
10.

An miRNA-DNMT1 Axis Is Involved in Azacitidine Resistance and Predicts Survival in Higher-Risk Myelodysplastic Syndrome and Low Blast Count Acute Myeloid Leukemia.

Solly F, Koering C, Mohamed AM, Maucort-Boulch D, Robert G, Auberger P, Flandrin-Gresta P, Adès L, Fenaux P, Kosmider O, Tavernier-Tardy E, Cornillon J, Guyotat D, Campos L, Mortreux F, Wattel E.

Clin Cancer Res. 2017 Jun 15;23(12):3025-3034. doi: 10.1158/1078-0432.CCR-16-2304. Epub 2016 Nov 23.

PMID:
27881579
11.

Acute myeloid leukemia in the elderly (age 70 yr or older): long-term survivors.

Heiblig M, Elhamri M, Le Jeune C, Laude MC, Deloire A, Wattel E, Salles G, Thomas X.

Eur J Haematol. 2017 Feb;98(2):134-141. doi: 10.1111/ejh.12811. Epub 2016 Oct 12.

PMID:
27717105
12.

A randomized phase II trial of azacitidine +/- epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents.

Thépot S, Ben Abdelali R, Chevret S, Renneville A, Beyne-Rauzy O, Prébet T, Park S, Stamatoullas A, Guerci-Bresler A, Cheze S, Tertian G, Choufi B, Legros L, Bastié JN, Delaunay J, Chaury MP, Sanhes L, Wattel E, Dreyfus F, Vey N, Chermat F, Preudhomme C, Fenaux P, Gardin C; Groupe Francophone des Myélodysplasies (GFM).

Haematologica. 2016 Aug;101(8):918-25. doi: 10.3324/haematol.2015.140988. Epub 2016 May 26.

13.

Treatment patterns and comparative effectiveness in elderly acute myeloid leukemia patients (age 70 years or older): the Lyon-university hospital experience.

Heiblig M, Le Jeune C, Elhamri M, Balsat M, Tigaud I, Plesa A, Barraco F, Labussière H, Ducastelle S, Nicolini F, Wattel E, Salles G, Thomas X.

Leuk Lymphoma. 2017 Jan;58(1):110-117. Epub 2016 May 17.

PMID:
27184036
14.

Treatment with Low-Dose Cytarabine in Elderly Patients (Age 70 Years or Older) with Acute Myeloid Leukemia: A Single Institution Experience.

Heiblig M, Elhamri M, Tigaud I, Plesa A, Barraco F, Labussière H, Ducastelle S, Michallet M, Nicolini F, Plesa C, Wattel E, Salles G, Thomas X.

Mediterr J Hematol Infect Dis. 2016 Jan 1;8(1):e2016009. doi: 10.4084/MJHID.2016.009. eCollection 2016.

15.

Cidofovir in the Treatment of BK Virus-Associated Hemorrhagic Cystitis after Allogeneic Hematopoietic Stem Cell Transplantation.

Philippe M, Ranchon F, Gilis L, Schwiertz V, Vantard N, Ader F, Labussiere-Wallet H, Thomas X, Nicolini FE, Wattel E, Ducastelle-Leprêtre S, Barraco F, Lebras L, Salles G, Michallet M, Rioufol C.

Biol Blood Marrow Transplant. 2016 Apr;22(4):723-730. doi: 10.1016/j.bbmt.2015.12.009. Epub 2015 Dec 21.

16.

Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion.

Toma A, Kosmider O, Chevret S, Delaunay J, Stamatoullas A, Rose C, Beyne-Rauzy O, Banos A, Guerci-Bresler A, Wickenhauser S, Caillot D, Laribi K, De Renzis B, Bordessoule D, Gardin C, Slama B, Sanhes L, Gruson B, Cony-Makhoul P, Chouffi B, Salanoubat C, Benramdane R, Legros L, Wattel E, Tertian G, Bouabdallah K, Guilhot F, Taksin AL, Cheze S, Maloum K, Nimuboma S, Soussain C, Isnard F, Gyan E, Petit R, Lejeune J, Sardnal V, Renneville A, Preudhomme C, Fontenay M, Fenaux P, Dreyfus F.

Leukemia. 2016 Apr;30(4):897-905. doi: 10.1038/leu.2015.296. Epub 2015 Oct 26.

17.

Adult T-Cell Leukemia/Lymphoma in a Caucasian Patient After Sexual Transmission of Human T-Cell Lymphotropic Virus Type 1.

Sibon D, Cassar O, Duga I, Brouzes C, Ghez D, Pasquier C, Sibon C, Desrames A, Mortreux F, Wattel E, Bazarbachi A, Gessain A, Hermine O.

Open Forum Infect Dis. 2015 Mar 6;2(2):ofv032. doi: 10.1093/ofid/ofv032. eCollection 2015 Apr.

18.

HBx triggers either cellular senescence or cell proliferation depending on cellular phenotype.

Idrissi ME, Hachem H, Koering C, Merle P, Thénoz M, Mortreux F, Wattel E.

J Viral Hepat. 2016 Feb;23(2):130-8. doi: 10.1111/jvh.12450. Epub 2015 Aug 28.

PMID:
26316075
19.

Effect of Initial Body Mass Index on Survival Outcome of Patients With Acute Leukemia: A Single-Center Retrospective Study.

Heiblig M, Elhamri M, Nicolini FE, Wattel E, Michallet M, Salles G, Thomas X.

Clin Lymphoma Myeloma Leuk. 2015 Jun;15 Suppl:S7-13. doi: 10.1016/j.clml.2015.02.005.

PMID:
26297282
20.

Oncogene- and drug resistance-associated alternative exon usage in acute myeloid leukemia (AML).

Mohamed AM, Balsat M, Thenoz M, Koering C, Payen-Gay L, Cheok M, Mortada H, Auboeuf D, Pinatel C, El-Hamri M, Dumontet C, Cros E, Flandrin-Gresta P, Nibourel O, Preudhomme C, Michallet M, Thomas X, Nicolini F, Solly F, Guyotat D, Campos L, Wattel E, Mortreux F.

Oncotarget. 2016 Jan 19;7(3):2889-909. doi: 10.18632/oncotarget.3898.

21.

Effect of Age on Treatment Decision-Making in Elderly Patients With Acute Myeloid Leukemia.

Fattoum J, Cannas G, Elhamri M, Tigaud I, Plesa A, Heiblig M, Plesa C, Wattel E, Thomas X.

Clin Lymphoma Myeloma Leuk. 2015 Aug;15(8):477-83. doi: 10.1016/j.clml.2015.02.022. Epub 2015 Mar 5.

PMID:
25843415
22.

HLA-matched allogeneic stem cell transplantation improves outcome of higher risk myelodysplastic syndrome A prospective study on behalf of SFGM-TC and GFM.

Robin M, Porcher R, Adès L, Raffoux E, Michallet M, François S, Cahn JY, Delmer A, Wattel E, Vigouroux S, Bay JO, Cornillon J, Huynh A, Nguyen S, Rubio MT, Vincent L, Maillard N, Charbonnier A, de Latour RP, Reman O, Dombret H, Fenaux P, Socié G.

Leukemia. 2015 Jul;29(7):1496-501. doi: 10.1038/leu.2015.37. Epub 2015 Feb 13.

PMID:
25676424
23.

HTLV-1-infected CD4+ T-cells display alternative exon usages that culminate in adult T-cell leukemia.

Thénoz M, Vernin C, Mortada H, Karam M, Pinatel C, Gessain A, Webb TR, Auboeuf D, Wattel E, Mortreux F.

Retrovirology. 2014 Dec 18;11:119. doi: 10.1186/s12977-014-0119-3.

24.

A phase I/II trial of Erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failure.

Thepot S, Boehrer S, Seegers V, Prebet T, Beyne-Rauzy O, Wattel E, Delaunay J, Raffoux E, Hunault M, Jourdan E, Chermat F, Sebert M, Kroemer G, Fenaux P, Adès L; Groupe Francophone des Myelodysplasies (GFM).

Leuk Res. 2014 Dec;38(12):1430-4. doi: 10.1016/j.leukres.2014.09.014. Epub 2014 Oct 7.

PMID:
25449687
25.

How mRNA is misspliced in acute myelogenous leukemia (AML)?

Mohamed AM, Thénoz M, Solly F, Balsat M, Mortreux F, Wattel E.

Oncotarget. 2014 Oct 30;5(20):9534-45. Review.

26.

HTLV-1 bZIP factor HBZ promotes cell proliferation and genetic instability by activating OncomiRs.

Vernin C, Thenoz M, Pinatel C, Gessain A, Gout O, Delfau-Larue MH, Nazaret N, Legras-Lachuer C, Wattel E, Mortreux F.

Cancer Res. 2014 Nov 1;74(21):6082-93. doi: 10.1158/0008-5472.CAN-13-3564. Epub 2014 Sep 9.

27.

Chromatin redistribution of the DEK oncoprotein represses hTERT transcription in leukemias.

Karam M, Thenoz M, Capraro V, Robin JP, Pinatel C, Lancon A, Galia P, Sibon D, Thomas X, Ducastelle-Lepretre S, Nicolini F, El-Hamri M, Chelghoun Y, Wattel E, Mortreux F.

Neoplasia. 2014 Jan;16(1):21-30.

28.

Prognostic impact of JAK2V617F mutation in myelodysplatic syndromes: A matched case control study.

de Renzis B, Mansat-De Mas V, Wattel E, Beyne-Rauzy O, Knoops L, Cabrespine A, Azgui Z, Ades L, Kiladjian JJ, Fenaux P; Groupe Francophone des Myelodysplasies (GFM), French Intergroup of Myeloproliferative disorders (FIM).

Leuk Res Rep. 2013 Aug 30;2(2):64-6. doi: 10.1016/j.lrr.2013.06.003. eCollection 2013.

29.

Mosaicism of HTLV-1 5' LTR CpG methylation in the absence of malignancy.

Sibon D, Zane L, Idrissi ME, Delfau-Larue MH, Gessain A, Gout O, Mortreux F, Wattel E.

Virus Res. 2013 Dec 26;178(2):452-61. doi: 10.1016/j.virusres.2013.08.010. Epub 2013 Sep 12.

PMID:
24036230
30.

Dental maturation in children with the syndrome of crouzon and apert.

Reitsma JH, Balk-Leurs IH, Ongkosuwito EM, Wattel E, Prahl-Andersen B.

Cleft Palate Craniofac J. 2014 Nov;51(6):639-44. doi: 10.1597/13-071. Epub 2013 Sep 10.

PMID:
24021057
31.

Cause-specific telomere factors deregulation in hepatocellular carcinoma.

El Idrissi M, Hervieu V, Merle P, Mortreux F, Wattel E.

J Exp Clin Cancer Res. 2013 Sep 11;32:64. doi: 10.1186/1756-9966-32-64.

32.

Combination of vorinostat and low dose cytarabine for patients with azacitidine-refractory/relapsed high risk myelodysplastic syndromes.

Prebet T, Braun T, Beyne-Rauzy O, Dreyfus F, Stammatoullas A, Wattel E, Ame S, Raffoux E, Delaunay J, Charbonnier A, Adès L, Fenaux P, Vey N.

Leuk Res. 2014 Jan;38(1):29-33. doi: 10.1016/j.leukres.2013.07.023. Epub 2013 Aug 13.

PMID:
23953882
33.

HTLV-1-associated inflammatory myopathies: low proviral load and moderate inflammation in 13 patients from West Indies and West Africa.

Desdouits M, Cassar O, Maisonobe T, Desrames A, Aouba A, Hermine O, Mikol J, Polivka M, Penisson-Besnier I, Marcorelles P, Zagnoli F, Papo T, Lacour A, Amoura Z, Haroche J, Cherin P, Teixeira A, Benveniste O, Herson S, Morin AS, Mortreux F, Wattel E, Huerre M, Cumont MC, Martin-Latil S, Butler-Browne G, Gout O, Taylor G, Gessain A, Ozden S, Ceccaldi PE.

J Clin Virol. 2013 May;57(1):70-6. doi: 10.1016/j.jcv.2012.12.016. Epub 2013 Jan 30.

PMID:
23375238
34.

Deep sequencing reveals abundant noncanonical retroviral microRNAs in B-cell leukemia/lymphoma.

Rosewick N, Momont M, Durkin K, Takeda H, Caiment F, Cleuter Y, Vernin C, Mortreux F, Wattel E, Burny A, Georges M, Van den Broeke A.

Proc Natl Acad Sci U S A. 2013 Feb 5;110(6):2306-11. doi: 10.1073/pnas.1213842110. Epub 2013 Jan 23.

35.

Antiretroviral therapy promotes an inflammatory-like pattern of human T-cell lymphotropic virus type 1 (HTLV-1) replication in human immunodeficiency virus type 1/HTLV-1 co-infected individuals.

Pomier C, Rabaaoui S, Pouliquen JF, Couppié P, El Guedj M, Nacher M, Lacoste V, Wattel E, Kazanji M, Mortreux F.

J Gen Virol. 2013 Apr;94(Pt 4):753-7. doi: 10.1099/vir.0.048348-0. Epub 2012 Dec 12.

PMID:
23239567
36.

Craniofacial morphology in unilateral hemifacial microsomia.

Ongkosuwito EM, van Neck JW, Wattel E, van Adrichem LN, Kuijpers-Jagtman AM.

Br J Oral Maxillofac Surg. 2013 Dec;51(8):902-7. doi: 10.1016/j.bjoms.2012.10.011. Epub 2012 Nov 30.

PMID:
23201060
37.

Heat Shock Protein 90 is overexpressed in high-risk myelodysplastic syndromes and associated with higher expression and activation of Focal Adhesion Kinase.

Flandrin-Gresta P, Solly F, Aanei CM, Cornillon J, Tavernier E, Nadal N, Morteux F, Guyotat D, Wattel E, Campos L.

Oncotarget. 2012 Oct;3(10):1158-68.

38.

Changes of mandibular ramal height, during growth in unilateral hemifacial microsomia patients and unaffected controls.

Ongkosuwito EM, van Vooren J, van Neck JW, Wattel E, Wolvius EB, van Adrichem LN, Kuijpers-Jagtman AM.

J Craniomaxillofac Surg. 2013 Mar;41(2):92-7. doi: 10.1016/j.jcms.2012.05.006. Epub 2012 Jul 11.

PMID:
22789870
39.

Long-term outcome of higher-risk MDS patients treated with azacitidine: an update of the GFM compassionate program cohort.

Itzykson R, Thépot S, Quesnel B, Dreyfus F, Recher C, Wattel E, Gardin C, Adès L, Fenaux P.

Blood. 2012 Jun 21;119(25):6172-3. doi: 10.1182/blood-2012-04-422204. No abstract available.

40.

Human T lymphotropic virus type 1 increases T lymphocyte migration by recruiting the cytoskeleton organizer CRMP2.

Varrin-Doyer M, Nicolle A, Marignier R, Cavagna S, Benetollo C, Wattel E, Giraudon P.

J Immunol. 2012 Feb 1;188(3):1222-33. doi: 10.4049/jimmunol.1101562. Epub 2012 Jan 6.

41.

Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents.

Sibon D, Cannas G, Baracco F, Prebet T, Vey N, Banos A, Besson C, Corm S, Blanc M, Slama B, Perrier H, Fenaux P, Wattel E; Groupe Francophone des Myélodysplasies.

Br J Haematol. 2012 Mar;156(5):619-25. doi: 10.1111/j.1365-2141.2011.08979.x. Epub 2011 Dec 23.

PMID:
22211483
42.

Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies.

Adès L, Le Bras F, Sebert M, Kelaidi C, Lamy T, Dreyfus F, Eclache V, Delaunay J, Bouscary D, Visanica S, Turlure P, Bresler AG, Cabrol MP, Banos A, Blanc M, Vey N, Delmer A, Wattel E, Chevret S, Fenaux P.

Haematologica. 2012 Feb;97(2):213-8. doi: 10.3324/haematol.2011.045914. Epub 2011 Oct 11.

43.

Intrinsic growth deficiencies of mesenchymal stromal cells in myelodysplastic syndromes.

Aanei CM, Flandrin P, Eloae FZ, Carasevici E, Guyotat D, Wattel E, Campos L.

Stem Cells Dev. 2012 Jul 1;21(10):1604-15. doi: 10.1089/scd.2011.0390. Epub 2011 Oct 27.

44.

Assessment of volumetric changes with a best-fit method in three-dimensional stereophotograms.

Ongkosuwito EM, Goos JA, Wattel E, van der Wal KG, van Adrichem LN, van Neck JW.

Cleft Palate Craniofac J. 2012 Jul;49(4):472-6. doi: 10.1597/10-270. Epub 2011 Aug 18.

PMID:
21851285
45.

HTLV-1 positive and negative T cells cloned from infected individuals display telomerase and telomere genes deregulation that predominate in activated but untransformed CD4+ T cells.

Zane L, Sibon D, Capraro V, Galia P, Karam M, Delfau-Larue MH, Gilson E, Gessain A, Gout O, Hermine O, Mortreux F, Wattel E.

Int J Cancer. 2012 Aug 15;131(4):821-33. doi: 10.1002/ijc.26270. Epub 2012 Apr 18.

46.

Telomere deregulations possess cytogenetic, phenotype, and prognostic specificities in acute leukemias.

Capraro V, Zane L, Poncet D, Perol D, Galia P, Preudhomme C, Bonnefoy-Berard N, Gilson E, Thomas X, El-Hamri M, Chelghoun Y, Michallet M, Wattel E, Mortreux F, Sibon D.

Exp Hematol. 2011 Feb;39(2):195-202.e2. doi: 10.1016/j.exphem.2010.10.008. Epub 2010 Nov 4.

PMID:
21056083
47.

Clonal expansion of HTLV-1 positive CD8+ cells relies on cIAP-2 but not on c-FLIP expression.

Zane L, Sibon D, Legras C, Lachuer J, Wierinckx A, Mehlen P, Delfau-Larue MH, Gessain A, Gout O, Pinatel C, Lançon A, Mortreux F, Wattel E.

Virology. 2010 Nov 25;407(2):341-51. doi: 10.1016/j.virol.2010.07.023. Epub 2010 Sep 22.

48.

Dental development in hemifacial microsomia.

Ongkosuwito EM, de Gijt P, Wattel E, Carels CE, Kuijpers-Jagtman AM.

J Dent Res. 2010 Dec;89(12):1368-72. doi: 10.1177/0022034510378425. Epub 2010 Aug 25.

PMID:
20739700
49.

Highly active antiretroviral treatment against STLV-1 infection combining reverse transcriptase and HDAC inhibitors.

Afonso PV, Mekaouche M, Mortreux F, Toulza F, Moriceau A, Wattel E, Gessain A, Bangham CR, Dubreuil G, Plumelle Y, Hermine O, Estaquier J, Mahieux R.

Blood. 2010 Nov 11;116(19):3802-8. doi: 10.1182/blood-2010-02-270751. Epub 2010 Jun 29.

50.

Tax gene expression and cell cycling but not cell death are selected during HTLV-1 infection in vivo.

Zane L, Sibon D, Jeannin L, Zandecki M, Delfau-Larue MH, Gessain A, Gout O, Pinatel C, Lançon A, Mortreux F, Wattel E.

Retrovirology. 2010 Mar 11;7:17. doi: 10.1186/1742-4690-7-17.

Supplemental Content

Loading ...
Support Center